UNICA IRIS Institutional Research Information System

LANZOLLA, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.715
NA - Nord America 1.911
AS - Asia 1.137
SA - Sud America 263
Continente sconosciuto - Info sul continente non disponibili 153
OC - Oceania 107
AF - Africa 43
Totale 6.329
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.401
US - Stati Uniti d'America 1.811
SG - Singapore 343
CN - Cina 339
BR - Brasile 181
VN - Vietnam 144
AU - Australia 102
BD - Bangladesh 80
NL - Olanda 67
FI - Finlandia 50
CA - Canada 48
HK - Hong Kong 45
IN - India 43
FR - Francia 34
ID - Indonesia 34
SE - Svezia 29
DE - Germania 28
GB - Regno Unito 25
AR - Argentina 22
LT - Lituania 21
MX - Messico 21
KR - Corea 20
PE - Perù 18
EC - Ecuador 13
CO - Colombia 12
PL - Polonia 12
JP - Giappone 11
DZ - Algeria 9
TR - Turchia 9
ZA - Sudafrica 9
JO - Giordania 8
RU - Federazione Russa 8
AT - Austria 7
CR - Costa Rica 7
IL - Israele 7
MA - Marocco 7
MY - Malesia 7
TH - Thailandia 7
CL - Cile 6
IE - Irlanda 6
IQ - Iraq 6
JM - Giamaica 6
UA - Ucraina 5
VE - Venezuela 5
ES - Italia 4
HN - Honduras 4
KE - Kenya 4
MG - Madagascar 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
SA - Arabia Saudita 4
BE - Belgio 3
GT - Guatemala 3
IR - Iran 3
PK - Pakistan 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
EG - Egitto 2
ET - Etiopia 2
GE - Georgia 2
KW - Kuwait 2
OM - Oman 2
PH - Filippine 2
PY - Paraguay 2
SV - El Salvador 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GP - Guadalupe 1
GR - Grecia 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
Totale 6.172
Salva come PNG Salva come JPEG
Città #
Cagliari 2.098
Ashburn 244
Dallas 220
Singapore 210
San Jose 159
Council Bluffs 102
Melbourne 77
Los Angeles 72
Beijing 66
Ho Chi Minh City 57
Hefei 51
Chicago 49
Hong Kong 38
Hanoi 37
Helsinki 37
New York 31
Santa Clara 30
Rome 26
Columbus 25
Amsterdam 23
São Paulo 23
Phoenix 20
Lauterbourg 19
Seoul 19
Vilnius 19
Salt Lake City 17
Heumen 16
Montreal 16
Atlanta 15
Buffalo 15
Guangzhou 14
Hengelo 14
Milan 14
Orem 14
Philadelphia 14
St Louis 14
Brooklyn 13
Redondo Beach 13
Lappeenranta 12
Tortolì 12
Mexico City 11
Miami 11
Boardman 10
North Bergen 10
San Francisco 10
Warsaw 10
Houston 9
Lima 9
Queens 9
Rende 9
Xi'an 9
Brisbane 8
Chennai 8
Frankfurt am Main 8
Rio de Janeiro 8
Sydney 8
Amman 7
Da Nang 7
Dublin 7
Jakarta 7
Maize 7
Manchester 7
Selargius 7
Denver 6
Genoa 6
Jacksonville 6
Johannesburg 6
Mainz 6
Palermo 6
Richmond 6
Washington 6
Bogotá 5
Bologna 5
Casalecchio di Reno 5
Elk Grove Village 5
Florence 5
Indianapolis 5
Las Vegas 5
Naples 5
New Delhi 5
Nuremberg 5
Sacramento 5
San José 5
Shenzhen 5
Tampa 5
Tokyo 5
Toledo 5
Algiers 4
Antananarivo 4
Auckland 4
Augusta 4
Bangkok 4
Bari 4
Brasília 4
Charlotte 4
Fortaleza 4
Guayaquil 4
Hercules 4
Hyderabad 4
Kingston 4
Totale 4.341
Salva come PNG Salva come JPEG
Nome #
Graves disease: latest understanding of pathogenesis and treatment options 945
Oxidative phosphorylation in bone cells 462
Risk of Neck Hematoma Following Thyroidectomy in Patients Taking Direct Oral Anticoagulants: A Propensity Score Matching Analysis from Nine High-Volume European Centers (RAGNO Study) 276
Editorial: News in Graves’ orbitopathy: patients management and treatments 223
Detection of Central Compartment Lymph Node Metastasis of Thyroid Cancer: Usefulness of Intraoperative Thyroglobulin Measurement in Fine Needle Aspiration Washout with and Without Blue Dye Injection 217
Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III) 187
Long-term outcome of Graves’ orbitopathy following treatment with sirolimus 173
Graves’ Disease: Is It Time for Targeted Therapy? A Narrative Review 172
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women 172
Osteoblastic erythropoietin is not required for bone mass accrual 165
HIF1 activation safeguards cortical bone formation against impaired oxidative phosphorylation 164
Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy 159
Ocular surface disease index in Graves’ orbitopathy: a cross-sectional study 157
Sirolimus as a second-line treatment for Graves’ orbitopathy 135
Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease 133
Pharmacological inhibition of HIF2 protects against bone loss in an experimental model of estrogen deficiency 131
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy 129
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-l1 blockade: Insights from four cases 112
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy 109
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves’ Orbitopathy: A Retrospective Cohort Study 106
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment 103
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 100
Antioxidant Therapy in Graves’ Orbitopathy 100
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ orbitopathy 96
IgG4 serum levels in Graves’ orbitopathy 92
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study 91
Absence of a relationship between vitamin D and Graves’ orbitopathy 72
Erythropoietin and skeletal cells crosstalks in physiology and disease 70
Insights into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 70
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy 61
Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression 59
Immune checkpoint blockade Anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome 59
Statins in Graves Orbitopathy: A New Therapeutic Tool 57
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols 55
Oxidative Stress in Graves Disease and Graves Orbitopathy 54
Early familial non-medullary thyroid cancer: differences with late-onset and sporadic forms 53
Genetic Profiling of Orbital Fibroblasts from Patients with Graves' Orbitopathy 53
Does preoperative administration of Lugol’s solution in patients undergoing thyroidectomy for Graves’ disease really improve surgical outcomes? A propensity score matching analysis from six high-volume centers (StELLinA study) 52
Androgens and Hypertension in Men and Women: a Unifying View 52
De-Escalating Thyroid Cancer Surgery: Insights and Unresolved Questions From the 2025 ATA Guidelines 47
Risk of Complications in Patients Undergoing Thyroidectomy for Graves' Disease (LUNA Study) 47
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 45
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 44
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 44
Graves’ disease and Graves’ orbitopathy following COVID-19 41
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 41
Statins: A New Hope on the Horizon of Graves Orbitopathy? 41
Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk 39
null 39
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study 36
The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX female 33
Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis 33
null 16
null 13
null 12
null 12
null 10
null 10
null 8
null 7
null 7
null 7
null 7
null 7
null 7
Totale 6.329
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.165 0 0 0 0 411 86 100 11 8 13 265 271
2025/20263.525 159 231 425 291 207 154 261 510 256 394 382 255
2026/20271.639 436 249 258 641 55 0 0 0 0 0 0 0
Totale 6.329